

May 22, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Intimation of Grant of Options under “Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016”

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that Nomination and Remuneration Committee of the Board of the Company at its Meeting held today, i.e. 22nd May, 2025 has granted 1,19,318 options pursuant to “Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016” to the eligible employee.

The details as required under Regulation 30 of SEBI Listing Regulations is enclosed herewith as Annexure -1.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure 1

Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sr. No.	Particulars	Details
1.	Brief details of options granted	1,19,318 options were granted pursuant to "Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016" to the eligible employee
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3.	Total number of shares covered by these options	Equity Shares of Re. 1/- each to be issued against 1,19,318 options pursuant to "Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016".
4.	Pricing formula	Rs. 600
5.	Options vested	-
6.	Time within which option may be exercised	Vesting of options will commence after a minimum period of one year from the date of the grant, and may extend up to a maximum period of six years from the date of the grant, with such lock in period as may be decided by the Board/Nomination & Remuneration Committee. Further, the Nomination & Remuneration Committee may on merits of the case relax/ extend the vesting period.
7.	Options exercised	-
8.	Money realized by exercise of options	-
9.	The total number of shares arising as a result of exercise of option	1,19,318 equity shares of Re. 1/- each
10.	Options lapsed	-
11.	Variation of terms of options	No variation/modification/amendment was made in the terms of options.
12.	Brief details of significant terms	The terms are finalised by the Nomination and Remuneration Committee in lines with the "Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016".
13.	Subsequent changes or cancellation or exercise of such options	-
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options	-

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com